This program addresses the lack of awareness of MA-PAH (methamphetamine associated pulmonary arterial hypertension), including its epidemiology, clinical characteristics, and known pathophysiology; improving early detection, screening, and diagnosis of MA-PAH; and integrating approaches to the treatment of MA-PAH that seek to address both the PAH and underlying substance use disorder.
This site uses cookies. By continuing to use this website, you agree to their use. For details, please check our Privacy Policy.